TP53 and neoplasm: In the context of cellular immunity and apoptosis, Rahnamoun et al. [49] reported a novel mechanism in which the mutant TP53 and KMT2B cooperated to regulate aberrant enhancer activity and tumor-promoting gene expression in response to chronic immune signaling.